Business Context and Reporting Period
This Form 8-K reports the consummation of the business combination between Zura Bio Limited ("Zura") and JATT Acquisition Corp ("JATT") on March 20, 2023. Following the closing, JATT changed its name to Zura Bio Limited and ceased being a shell company. The combined entity now trades on The Nasdaq Capital Market under the symbols "ZURA" (Class A Ordinary Shares) and "ZURAW" (Warrants).
Key Financial Metrics and Capital Structure
The filing details the capitalization and financing activities surrounding the closing date. Specific revenue, profit, or cash flow figures for the combined entity are not provided in this text; however, the following capital metrics are disclosed:
- Shareholder Redemptions: Approximately 13,617,502 JATT ordinary shares were redeemed for an aggregate amount of approximately $139.7 million at a price of roughly $10.26 per share.
- Merger Consideration: Holdco securityholders received newly issued Company Class A Ordinary Shares and options with an aggregate value of $165 million.
- PIPE Financing: Institutional investors (Ewon Comfortech Co., Ltd. and Eugene Investment & Securities Co., Ltd.) purchased 2,009,950 shares at $10.00 per share, raising approximately $20.1 million.
- Forward Purchase Agreement (FPA): Athanor Master Fund, LP and Athanor International Master Fund, LP purchased 4,301,633 shares for approximately $43.0 million ($30 million for base shares and $13 million for redemption backstop shares). An additional 2.5 million shares were issued for no additional monetary consideration.
- Debt Repayment: Zura repaid a $8 million promissory note to Hydra LLC in full on March 21, 2023, paying 125% of the principal amount ($10 million) to settle the obligation.
- Outstanding Securities (Post-Closing):
- 27,552,148 Class A Ordinary Shares
- 6,900,000 Public Warrants (exercise price $11.50)
- 5,910,000 Private Placement Warrants (exercise price $11.50)
- 2,248,306 Options
Material Changes Versus Prior Period
The primary material change is the transition from a pre-merger SPAC structure to a combined operating company. Key changes include:
- Corporate Status: JATT ceased to be a shell company.
- Ownership Structure: Significant dilution occurred due to the issuance of shares to Holdco shareholders, PIPE investors, and FPA investors. Pre-merger JATT shareholders retained approximately 13.2% of the post-closing equity.
- Liquidity Event: The company raised significant capital through the PIPE and FPA transactions while simultaneously reducing cash via shareholder redemptions totaling nearly $140 million.
- Debt Elimination: The $8 million Hydra promissory note was extinguished immediately following the closing.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing contains standard forward-looking statements regarding the company's ability to recognize benefits from the combination, expand operations, and raise future financing. No specific financial guidance or revenue projections are included in this text.
Risks and Contingencies: The filing incorporates by reference risk factors from the Proxy Statement/Prospectus, including:
- Ability to obtain regulatory approval for product candidates.
- Future capital requirements and ability to raise financing.
- Competition from larger pharmaceutical companies.
- Impact of pandemics and economic disruptions.
- Cybersecurity threats.
Unusual Items:
- Redemption Backstop: Due to public share redemptions exceeding 90% of the trust, FPA investors were required to purchase additional shares (the "Redemption Backstop") to ensure sufficient cash for the transaction.
- Debt Settlement Premium: Zura paid a 25% premium ($2 million) over the principal amount to settle the Hydra promissory note to waive acceleration rights.
- Lock-Up Agreements: Significant portions of shares held by insiders, the Sponsor, and Eli Lilly are subject to lock-up restrictions for 6, 12, and 24 months, with early release provisions if the share price exceeds $12.00.
Important Facts for Investor Verification
- Post-Closing Cash Position: Verify the net cash balance after accounting for the ~$140 million in redemptions, the ~$63 million in new equity financing (PIPE + FPA), and the $10 million debt repayment.
- Share Ownership Concentration: Athanor Capital holds approximately 27.0% and Hana Immunotherapeutics LLC holds 19.6% of the outstanding shares.
- Warrant Dilution: Confirm the total number of warrants (Public and Private) exercisable at $11.50, which represents significant potential dilution if the share price rises above this level.
- Lock-Up Expiration: Monitor the lock-up expiration dates (6, 12, and 24 months) and the $12.00 price trigger for early release of restricted shares.
- Financial Statements: Review the unaudited pro forma financial information (Exhibit 99.1) and the audited financials of Zura and JATT referenced in the Proxy Statement/Prospectus for detailed historical performance.